Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy

AIDS

Volumn 24, Issue 8, 2010, Pages 1235-1236

  De Truchis, Pierre ^a   Mathez, Dominique ^b   Abe, Emuri ^c   Dinh, Aurelien ^a   Ledu, Damien ^a   Greder Belan, Alix ^d   Alvarez, Jean Claude ^c  

^a Infectious Disease Department   (France)

^b Virology Unit   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; TENOFOVIR DISOPROXIL; TETRAHYDROLIPSTATIN; ZIDOVUDINE;

ADULT; ASTHENIA; CASE REPORT; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID EXAMINATION; CEREBROSPINAL FLUID LEVEL; DELIVERY; DIZZINESS; DRUG BLOOD LEVEL; DRUG PENETRATION; ENCEPHALITIS; FEMALE; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; LETTER; LYMPHOCYTIC MENINGOENCEPHALITIS; MENINGITIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PLEOCYTOSIS; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD; VIRUS RESISTANCE; VISUAL FIELD DEFECT;

HIV INFECTIONS; HIV-1; HUMANS; MENINGITIS, VIRAL; PYRIMIDINONES; RITONAVIR;

EID: 77951829518     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283386563     Document Type: Letter

References (15)

1. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21:1915-1921. (Pubitemid 47329768)
2. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197:S294-S306. (Pubitemid 351717319)
3. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cere-brospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
4. Letendre S, Marquie-Beck J, Caparelli E, Best B, Clifford D, Collier AC, et al., CHARTER Group. Validation of the CNS Penetration effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
5. Garvey LJ, Everitt A, Winston A, Mackie NE, Benzie A. Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment. AIDS 2009; 23:1443-1444.
6. Letendre SL, Van den Brande G, Hermes A, Woods SP, Durelle J, Beck JM, et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Inf Dis 2007; 45:1511-1517. (Pubitemid 351411885)
7. Yilmaz A, Gisslen M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4:e6877.
8. Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmermann P, Gisslen M. Darunavir concentrations in cere-brospinal fluid and blood in HIV-1 infected individuals. AIDS Res Hum Retroviruses 2009; 25:457-461.
9. Yilmaz A, Stahle L, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Cerebrospinal fluid and plasma HIV-RNA levels and lopi-navir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis 2004; 36:823-828. (Pubitemid 40074016)
10. Bierman WF, Van Agtmael MA, NijhuisM, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-291.
11. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, Perez-Elias MJ, et al., OKO4 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
12. Arribas J, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al. The MONET Trial: darunavir/ritonavir mono-therapy shows noninferior efficacy to standard HAART for patients with HIV-RNA
13. Katlama C, Valentin MA, Algarte-Genin M, Duvivier C, Lam-bert-Nicot S, Girard PM, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non inferiority trial, MONOI-ANRS 136. 5th IAS;2009; Cape Town. p.3689
14. Katlama C, Valentin MA, Algarte-Genin M, Duvivier C, Lam-bert-Nicot S, Girard PM, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non inferiority trial, MONOI-ANRS 136. 5th IAS; 2009; Cape Town. p. 3689.
15. Gutmann C, Opravil M, Yerly S, Fux C, Furrer H, Cavassini M, et al. Swiss HIV Cohort. Low nadir CD4 cell count predicts failure of monotherapy maintenance with ritonavir-boosted lopinavir: results after premature termination of a randomized study due to unexpected high failure rate in the monotherapy arm. 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal; abstract 578.